Cook MyoSite
Biotechnology ResearchPennsylvania, United States201-500 Employees
Cook MyoSite is a biotechnology company focused on developing muscle cell–based therapies with the goal of integrating regenerative medicine into routine clinical care. Founded in 2002, the firm is based in Pittsburgh, Pennsylvania, and operates within the Cook Group network. The company concentrates on skeletal muscle biology to address disorders affecting muscle tissue and maintains a mid-sized team to advance its programs. In 2025, Cook MyoSite entered into a collaboration with Veristat to support the DigniFI study, a Phase III trial evaluating iltamiocel versus placebo for chronic fecal incontinence in women with a history of obstetric anal sphincter injury.